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Oxidative stress, defined as an alteration in the balance
between the production and removal of reactive oxygen
species (ROS), plays a central role in many cardiovascular
diseases. ROS disturb the vasoprotective nitric oxide-solu-
ble guanylate cyclase-cyclic GMP (NO-sGC-cGMP) signal-
ing cascade by downregulation of the NO-sensitive form
of sGC and, in addition, a direct impairment of this cru-
cial enzyme by oxidizing its prosthetic heme moiety.
Through a high-throughput screen we identified non NO-
releasing sGC activators, such as BAY 58-2667, acting
more potently at the oxidized or heme free recombinant
sGC than at the native form. Here, we show that the activ-
ity of BAY 58-2667 is potentiated in cells, aortas from dif-
ferent species and in vivo under oxidative stress conditions
(ROS generating systems, ODQ, and hypercholesteremia)
indicating the presence of heme-free or oxidized sGC
under pathophysiological conditions. Moreover, in vari-
ous long-term trials beneficial effects on morbidity and
mortality have been observed in BAY 58-2667 treated ani-
mals. Consequently, the intracellular pool of oxidation-
impaired sGC can be reactivated by BAY 58-2667 to over-
come the pathophysiology of the impaired NO/sGC/
cGMP signaling pathway.
Moreover, by using the NO- and heme-indepent sGC acti-
vator BAY 58-2667, the heme-dependent sGC stimulator
BAY 41-2272, NO, ODQ together with a novel cGMP
reporter cell line, it was possible to distinguish between
heme-containing and heme-free sGC in an intact cellular
system. The investigation of the activation profile of dif-
ferent sGC mutants by transient transfection into the
cGMP reporter cell led to the identification of the heme
binding motif Tyr135-x-Ser137-x-Arg139 in addition to
His105. Very recently, crystallization studies of a prokary-
otic homologue of the sGC heme binding domain have
confirmed our findings and proposed further amino acids
involved in sGC signalling (Pellicena et al., 2004).
Accordingly, a 3-dimensional model of sGC was con-
structed and we identified the β-subunit amino acids
Asp44, Asp45 and Phe74 as also being crucially important
for the heme-induced sGC activation.
Our studies demonstrate that sGC activators, exemplified
by BAY 58-2667, offer new approaches for the under-
standing of sGC activation and for the treatment of oxida-
tion-damaged vasculature by a selective targeting of
oxidized sGC.
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